Skip to main content
Livermore
Livermore
ZHEN

Paradigm Biocapital Advisors LP

SEC CIK
0001855655
Latest filing
Aug 14, 2026

The latest 13F from Paradigm Biocapital Advisors LP covers Q2 2026 (filed Aug 14, 2026): 28 long positions worth $5.34B. The top 10 holdings make up 75.2% of the portfolio, and the largest is Revolution Medicines, Inc. (RVMD) at 22.3%. Livermore has 19 filings on Form 13F from this institution, going back to Q4 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
7
Est. +$442.9M
Added
12
Est. +$740.2M
Reduced
7
Est. −$262.4M
Sold out
14
Est. −$1.43B

Top 5 holdings

Share of this quarter's portfolio value

  1. RVMDRevolution Medicines, Inc.
    22.3%$1.19BHistory
  2. NUVLNuvalent, Inc.
    13.7%$731.7MHistory
  3. EWTXEdgewise Therapeutics, Inc.
    7.8%$415.1MHistory
  4. GMABGenmab A/S
    6.8%$360.8MHistory
  5. SYRESpyre Therapeutics, Inc.
    6.4%$341.0MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. SYRESpyre Therapeutics, Inc.
    +$167.2MAddedHistory
  2. ALNYAlnylam Pharmaceuticals, Inc.
    +$144.5MNewHistory
  3. GMABGenmab A/S
    +$141.9MAddedHistory
  4. MBXMBX Biosciences, Inc.
    +$138.4MNewHistory
  5. EWTXEdgewise Therapeutics, Inc.
    +$115.8MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. SYRESpyre Therapeutics, Inc.
    +4.37 pp2.0% → 6.4%History
  2. EWTXEdgewise Therapeutics, Inc.
    +3.03 pp4.7% → 7.8%History
  3. ALNYAlnylam Pharmaceuticals, Inc.
    +2.71 pp0.0% → 2.7%History
  4. MBXMBX Biosciences, Inc.
    +2.59 pp0.0% → 2.6%History
  5. NUVLNuvalent, Inc.
    +2.55 pp11.1% → 13.7%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. ACLXArcellx, Inc.
    −$663.0MSold outHistory
  2. PCVXVaxcyte, Inc.
    −$154.9MReducedHistory
  3. CNTACentessa Pharmaceuticals plc
    −$142.0MSold outHistory
  4. TERNTerns Pharmaceuticals, Inc.
    −$116.9MSold outHistory
  5. CYTKCytokinetics Inc
    −$97.6MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. ACLXArcellx, Inc.
    −13.55 pp13.5% → 0.0%History
  2. PCVXVaxcyte, Inc.
    −3.37 pp5.7% → 2.3%History
  3. CNTACentessa Pharmaceuticals plc
    −2.90 pp2.9% → 0.0%History
  4. TERNTerns Pharmaceuticals, Inc.
    −2.39 pp2.4% → 0.0%History
  5. CYTKCytokinetics Inc
    −1.99 pp2.0% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$5.34B
+$446.3M (+9.1%) vs. prior quarter
Positions
28
−7 vs. prior quarter
Top 10 concentration
75.2%
Top 10 as share of value
Turnover
23.1%
Q2 2026, one quarter
Average holding period
8.1 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.

13F filings by quarter

19 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $5.34B (Q2 2026)

Q4 2021: $350.2MQ1 2022: $378.2MQ2 2022: $501.5MQ3 2022: $710.1MQ4 2022: $851.9MQ1 2023: $1.06BQ2 2023: $1.24BQ3 2023: $1.47BQ4 2023: $2.13BQ1 2024: $2.84BQ2 2024: $2.61BQ3 2024: $2.86BQ4 2024: $2.87BQ1 2025: $2.17BQ2 2025: $2.34BQ3 2025: $3.38BQ4 2025: $3.73BQ1 2026: $4.89BQ2 2026: $5.34B
Q4 2021Q2 2026
13F filings of Paradigm Biocapital Advisors LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202628$5.34BRVMDNUVLEWTXvs. Q1 2026SEC
Q1 2026May 15, 202635$4.89BACLXRVMDNUVLvs. Q4 2025SEC
Q4 2025Feb 17, 202629$3.73BNUVLRVMDACLXvs. Q3 2025SEC
Q3 2025Nov 14, 202533$3.38BNUVLMRUSACLXvs. Q2 2025SEC
Q2 2025Aug 14, 202528$2.34BNUVLACLXMRUSvs. Q1 2025SEC
Q1 2025May 15, 202527$2.17BNUVLACLXRVMDvs. Q4 2024SEC
Q4 2024Feb 14, 202528$2.87BNUVLACLXARGXvs. Q3 2024SEC
Q3 2024Nov 14, 202431$2.86BNUVLACLXARGXvs. Q2 2024SEC
Q2 2024Aug 14, 202435$2.61BNUVLARGXACLXvs. Q1 2024SEC
Q1 2024May 15, 202434$2.84BNUVLACLXARGXvs. Q4 2023SEC
Q4 2023Feb 14, 202429$2.13BNUVLACLXARGXvs. Q3 2023SEC
Q3 2023Nov 14, 202329$1.47BLEGNARGXACLXvs. Q2 2023SEC
Q2 2023Aug 14, 202329$1.24BLEGNINCYIMCRvs. Q1 2023SEC
Q1 2023May 15, 202325$1.06BBIIBINCYLEGNvs. Q4 2022SEC
Q4 2022Feb 14, 202323$851.9MINCYBIIBMRTXvs. Q3 2022SEC
Q3 2022Nov 14, 202227$710.1MGBTMRTXINCYvs. Q2 2022SEC
Q2 2022Aug 15, 202223$501.5MLEGNGBTMRTXvs. Q1 2022SEC
Q1 2022May 16, 202225$378.2MASNDGBTARVNvs. Q4 2021SEC
Q4 2021Feb 14, 202224$350.2MMRTXASNDZNTL–SEC

13D and 13G filings

Companies where Paradigm Biocapital Advisors LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

9 companies, largest stake first.

Companies where Paradigm Biocapital Advisors LP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
OLMAOlema Pharmaceuticals, Inc.13G/A9.99%7.43M shares–Apr 10, 20235 filingsFeb 14, 2025SEC
EWTXEdgewise Therapeutics, Inc.13G/A9.50%10.2M shares+3.30 ppfrom 6.20%Feb 3, 20253 filingsAug 14, 2026SEC
ACHVAchieve Life Sciences, Inc.13G9.20%9.90M sharesNewApr 24, 20261 filingApr 24, 2026SEC
ASMBAssembly Biosciences, Inc.13G/A7.80%1.55M shares+2.40 ppfrom 5.40%May 11, 20262 filingsAug 14, 2026SEC
VRDNViridian Therapeutics, Inc.13G/A6.10%6.72M shares+1.00 ppfrom 5.10%Feb 14, 20227 filingsAug 14, 2026SEC
TYRATyra Biosciences, Inc.13G5.80%3.47M sharesNewSep 17, 20261 filingSep 17, 2026SEC
LXEOLexeo Therapeutics, Inc.13G/A5.30%4.18M shares−3.00 ppfrom 8.30%Nov 20, 20254 filingsAug 14, 2026SEC
MBXMBX Biosciences, Inc.13G5.20%2.49M sharesNewJun 24, 20261 filingJun 24, 2026SEC
JBIOJade Biosciences, Inc.13G5.10%3.11M sharesNewJul 17, 20261 filingJul 17, 2026SEC

Latest filings

96 filings on file made by Paradigm Biocapital Advisors LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Paradigm Biocapital Advisors LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
TYRATyra Biosciences, Inc.Sep 17, 20264:06 PM ET13G5.80%3.47M sharesNewSep 10, 2026SEC
ACLXArcellx, Inc.Aug 14, 20264:23 PM ET13G/A0.00%0 shares−9.90 ppfrom 9.90%Below 5%Jun 30, 2026SEC
ASMBAssembly Biosciences, Inc.Aug 14, 20264:23 PM ET13G/A7.80%1.55M shares+2.40 ppfrom 5.40%Jun 30, 2026SEC
VRDNViridian Therapeutics, Inc.Aug 14, 20264:22 PM ET13G/A6.10%6.72M shares+1.00 ppfrom 5.10%Jun 30, 2026SEC
LXEOLexeo Therapeutics, Inc.Aug 14, 20264:22 PM ET13G/A5.30%4.18M shares−3.00 ppfrom 8.30%Jun 30, 2026SEC
EWTXEdgewise Therapeutics, Inc.Aug 14, 20264:22 PM ET13G/A9.50%10.2M shares+3.30 ppfrom 6.20%Jun 30, 2026SEC
MAZEMaze Therapeutics, Inc.Aug 14, 20264:21 PM ET13G/A0.00%0 shares−6.10 ppfrom 6.10%Below 5%Jun 30, 2026SEC
JBIOJade Biosciences, Inc.Jul 17, 20264:05 PM ET13G5.10%3.11M sharesNewJul 10, 2026SEC
VRDNViridian Therapeutics, Inc.Jun 26, 20264:05 PM ET13G5.10%5.63M shares–Jun 18, 2026SEC
MBXMBX Biosciences, Inc.Jun 24, 20264:05 PM ET13G5.20%2.49M sharesNewJun 16, 2026SEC
EYPTEyePoint, Inc.May 15, 20264:26 PM ET13G/A3.80%3.14M shares−1.30 ppfrom 5.10%Below 5%Mar 31, 2026SEC
URGNUroGen Pharma Ltd.May 15, 20264:25 PM ET13G/A3.50%1.70M shares−5.50 ppfrom 9.00%Below 5%Mar 31, 2026SEC
LXEOLexeo Therapeutics, Inc.May 15, 20264:25 PM ET13G/A8.30%6.18M shares+1.80 ppfrom 6.50%Mar 31, 2026SEC
ERASErasca, Inc.May 15, 20264:25 PM ET13G/A3.30%10.4M shares−2.00 ppfrom 5.30%Below 5%Mar 31, 2026SEC
ASMBAssembly Biosciences, Inc.May 11, 20264:02 PM ET13G5.40%865.3K sharesNewMay 4, 2026SEC
ACHVAchieve Life Sciences, Inc.Apr 24, 20268:12 PM ET13G9.20%9.90M sharesNewApr 17, 2026SEC
MAZEMaze Therapeutics, Inc.Apr 1, 20264:00 PM ET13G6.10%3.05M sharesNewMar 25, 2026SEC
EYPTEyePoint, Inc.Feb 24, 20264:00 PM ET13G5.10%4.19M sharesNewFeb 17, 2026SEC
MRUSMerus N.V.Feb 17, 20264:03 PM ET13G/A0.00%0 shares−6.20 ppfrom 6.20%Below 5%Dec 31, 2025SEC
ACLXArcellx, Inc.Feb 17, 20264:03 PM ET13G/A9.90%5.72M shares–Dec 31, 2025SEC